Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid - Lupin Ltd

Code BSE: 500257 NSE:

Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid Lupin Ltd announced that it has received approval from the United States Food and Drug Administration for its AbbreviatedNew Drug Applicationsfor Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. The product sales for Glycerol Phenylbutyrate Oral Liquid (RLD Ravicti) were USD 337 million for the year ended December 2025